Immunovia Publ (Sweden) Top Management
IMMNOV Stock | SEK 0.63 0.01 1.61% |
Immunovia Publ employs about 64 people. The company is managed by 4 executives with a total tenure of roughly 6 years, averaging almost 1.0 years of service per executive, having 16.0 employees per reported executive. Analysis of Immunovia Publ's management performance can provide insight into the company performance.
Linda Mellby Director Laboratory Director |
Jeff Borcherding Insider Immunovia, US |
Immunovia |
Immunovia Publ Management Team Effectiveness
The company has return on total asset (ROA) of (0.2617) % which means that it has lost $0.2617 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3789) %, meaning that it generated substantial loss on money invested by shareholders. Immunovia Publ's management efficiency ratios could be used to measure how well Immunovia Publ manages its routine affairs as well as how well it operates its assets and liabilities.Immunovia Publ Workforce Comparison
Immunovia publ AB is currently regarded as number one stock in number of employees category among its peers. The total workforce of Diagnostics & Research industry is currently estimated at about 2,634. Immunovia Publ holds roughly 64.0 in number of employees claiming about 2.43% of equities under Diagnostics & Research industry.
Immunovia publ AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Immunovia publ AB Price Series Summation is a cross summation of Immunovia Publ price series and its benchmark/peer.
Immunovia Publ Notable Stakeholders
An Immunovia Publ stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immunovia Publ often face trade-offs trying to please all of them. Immunovia Publ's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immunovia Publ's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Linda Mellby | Laboratory Director | Profile | |
Jeff Borcherding | Immunovia, US | Profile | |
Philipp Mathieu | CEO Pres | Profile | |
Karin Liwendahl | Chief Officer | Profile |
About Immunovia Publ Management Performance
The success or failure of an entity such as Immunovia publ AB often depends on how effective the management is. Immunovia Publ management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immunovia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immunovia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.
Please note, the presentation of Immunovia Publ's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunovia Publ's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Immunovia Publ's management manipulating its earnings.
Immunovia Publ Workforce Analysis
Traditionally, organizations such as Immunovia Publ use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immunovia Publ within its industry.Immunovia Publ Manpower Efficiency
Return on Immunovia Publ Manpower
Revenue Per Employee | 13.2K | |
Revenue Per Executive | 211K | |
Net Loss Per Employee | 2.6M | |
Net Loss Per Executive | 41.7M |
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data |